Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Effexor · 3 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Effexor XR | DRUG | - |
| Milnacipran | DRUG | - |
Inclusion Criteria: * Patients who complete the Phase III double-blind study (Protocol Number 0600B1-816) Exclusion Criteria: * Patients with schizophrenia or any other psychotic disorder * Patients with history or presence of bipolar disorder
Effexor is used for the treatment of depression. It is a small molecule being developed by Pfizer, Inc. for this psychiatric condition. The drug has been studied in Phase 3 clinical trials, all of which have been completed, with a total enrollment of 840 patients across three studies.
Effexor is developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company has conducted Phase 3 clinical trials for Effexor in the treatment of depression. All three trials have been completed, with no active trials currently ongoing.
Effexor is in Phase 3 clinical development for depression. All three Phase 3 trials have been completed, and there are no active trials currently enrolling. The drug is investigational and has not been reported as approved based on the available data.
Effexor has been studied in three completed Phase 3 clinical trials: NCT00225485, a study in elderly patients with major depression; NCT00225511, a study for major depression; and NCT00225524, a long-term safety study. All trials were conducted in Japan and enrolled a total of 840 patients.
Based on the available data, Effexor is an investigational drug that has completed Phase 3 clinical trials for depression. The information does not indicate that it has received FDA approval. It remains in clinical development, with all trials completed and no active studies ongoing.